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Biological therapies targeting cytokines, T cells, or B cells have improved outcomes of inflammatory dis-
eases. However, many issues remain open: What is the best target? How well can response be predicted?
How can cure be achieved?Introduction
The etiology of immune-mediated
inflammatory diseases (IMIDs), such as
rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), ankylosing spondy-
litis (AS), psoriatic arthritis (PsA), psoria-
sis, juvenile inflammatory arthritis (JIA),
or inflammatory bowel disease (IBD),
remains enigmatic. These disorders can
lead to severe organ damage and prema-
ture death. On the basis of insights into
presumed pathogenetic events, gener-
ated over the past two decades, various
therapies specifically targeting molecules
involved in these pathways have been
successfully developed.
RA, a disease that can destroy the joints
and is associated with physical disability
and enhanced mortality, is likely the best
prototypic example for the success of tar-
geted therapeutics, for several reasons.
First, it was the first IMID in which such
therapy was proven to be efficacious
(Elliott et al., 1994). Second, it is the
IMID with the largest range of available
biological therapeutics (Smolen et al.,
2007), and furthermore, many of these
drugs are also effective against other
IMIDs.
Cells and Cytokines as Pathogenic
Culprits and Therapeutic Targets
A variety of cells and cytokines are
involved in the pathogenesis of RA
[reviewed in (Smolen et al., 2007)]. It is
believed that in individuals who are pre-
disposed primarily by carrying a particular
major histocompatibility complex (MHC)
phenotype, unknown (auto-)antigen(s)
are presented by antigen-presenting cells
(APCs), such as dendritic cells (DCs),
leading to T cell activation. This activation
requires additional signaling by costimu-440 Immunity 28, April 2008 ª2008 Elsevierlatory molecules. Once triggered, T cells
activate other cells, especially B cells.
These activated B cells then likely pro-
duce autoantibodies. T cells also activate
macrophages, which secrete a variety of
proinflammatory cytokines, including
tumor necrosis factor a (TNF), interleu-
kin-1 (IL-1), and IL-6. Autoantibodies,
once formed, may form immune com-
plexes that in turn can augment macro-
phage activation. The proinflammatory
cytokines enhance the recruitment, via
activation of endothelial cells, of further
inflammatory cells into the joint and
induce fibroblasts, chondrocytes, and
osteoclasts to secrete a variety of inflam-
matory molecules, including many prote-
ases, which ultimately lead to the swelling
and pain, cartilage and bone destruction,
and disability typical of RA. They have
many activities in common or act in an
additive manner, and some may induce
others to further improve host defense.
Many of these molecules constitute
successful therapeutic targets (Figure 1).
Targeted Therapies and Their
Proposed Mechanisms of Action
Direct evidence for the pathogenetic
involvement of proinflammatory cytokines
in RA was provided in the first controlled
trial of a monoclonal antibody to TNF
(Elliott et al., 1994). Meanwhile, three
TNF inhibitors, Etanercept [a construct
of TNF receptor (R)2 with an Fc portion
of immunoglobulin G], Infliximab (a chime-
ric monoclonal antibody), and adalimu-
mab (a human monoclonal antibody), are
approved for RA, but also for PsA and
AS, and an additional two are expected
soon (Certolizumab pegol, a pegylated
monoclonal Fab’ fragment, and Golimu-
mab, a human monoclonal antibody).Inc.TNF inhibition is clinically highly effica-
cious: In combination with a synthetic
drug, methotrexate (MTX), a 50% reduc-
tion of clinical signs and symptoms is
observed in about 50%–70% of treated
patients, compared to about 30%–50%on
MTX (or biological agent) alone (Smolen
et al., 2007). Probably the most impres-
sive aspect of TNF-blocking therapies
(plus MTX) is the profound retardation,
or often halt, of joint destruction, which
even occurs when clinical disease activity
continues (Smolen et al., 2005) and can
be explained by inhibition of the agonistic
effects of TNF on the differentiation and
activation of osteoclasts, the cells re-
sponsible for the characteristic bone de-
struction of RA. Interestingly, although all
TNF inhibitors are efficacious in several
other IMIDs, such as AS, PsA, and psoria-
sis, only the monoclonal antibodies, not
the TNF-R2 construct Etanercept, are
able to ameliorate Crohn’s disease (Sand-
born and Targan, 2002).
Inhibition of IL-1 with the IL-1 receptor
antagonist (IL-1Ra) Anakinra (which pre-
vents IL-1 from activating its receptor) is
also approved and improves RA, although
only 17% of patients (compared to 6% of
controls) respond by 50%ormore (Cohen
et al., 2002). This relatively low efficacy in
RA patients is in stark contrast to the pro-
found improvement and even complete
reversal of symptoms conveyed by
Anakinra in autoinflammatory syndromes
including neonatal-onset multisystem
inflammatory disease (NOMID) (Gold-
bach-Mansky et al., 2006) and its efficacy
in juvenile- and adult-onset Still’s disease.
This suggests that, indeed, IL-1Ra is
highly effective systemically under cir-
cumstances of otherwise potentially
lethal, highly febrile disorders. Therefore,
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CommentaryFigure 1. Presumed Pathogenetic Pathways Involved in Rheumatoid Arthritis
For symbols, please see inserted legend.
Top: An antigen-presenting cell (APC), such as a dendritic cell, presents an (auto)antigen via its major his-
tocompatibility complex (MHC)-encodedmolecules to the specific T cell receptor. For activation, the T cell
requires engagement of its CD28 receptor with costimulatory molecules (CD80 or CD86). Under normal
circumstances, cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed on activated T cells and upon
binding to CD80 or 86 downregulates T cell activity (not depicted). Abatacept, a construct of CTLA-4
with an Fc portion of an immunoglobulin G (IgG), binds CD80 and CD86 and thus prevents their engage-
ment with CD28, consequently inhibiting T cell costimulation.
Center: B cells constitute the progeny of (auto)antibody-secreting cells and themselves can serve as APCs
by presenting antigen via their MHC and expressing costimulatory molecules such as CD80 and CD86.
CD20 is a differentiation antigen of B lymphocytes. Rituximab (anti-CD20) leads to depletion of B lympho-
cytes, thus eliminating their pathogenetic involvement.
Bottom: Monocytes andmacrophages, which can be activated by T cells (but can also serve as APCs and
present antigens and costimulatory molecules to T cells), secrete proinflammatory cytokines such as TNF,
IL-1, and IL-6, which can engage specific receptors that are expressed on many cell populations (such as
monocytes, macrophages, osteoclasts, chondrocytes, and fibroblasts), leading to their activation. TNF in-
hibitors, such as the human monoclonal antibody adalimumab, the construct of TNF receptor (R)2 with an
Fc portion of IgG (Etanercept), or the chimeric monoclonal antibody Infliximab, can bind TNF effectively
and thus prevent its engagement with the receptor. The IL-1 receptor antagonist (IL-1Ra, or Anakinra)
can engage the IL-1R, thus preventing IL-1 from activating its receptor. Tocilizumab, a humanized anti-
body to the IL-6R, binds both its membrane and its soluble form and prevents IL-6 engagement and sub-
sequent cell activation via the gp130 chain (not depicted). Effector cells of the final pathogenetic pathways
in the joint are osteoclasts leading to bone destruction, chondrocytes leading to cartilage damage, and
fibroblasts leading to cartilage damage and propagating synovial inflammation. Please note that all com-
pounds mentioned here are approved for the treatment of RA, except for tocilizumab, which has recently
finalized phase III trials and will undergo regulatory authority review in the near future. Certolizumab pegol
andGolimumab are additional TNF inhibitors that are not yet approved and will undergo regulatory author-
ity review.IL-1 plays no important role in RA, it does
not sufficiently accumulate in joints, or it
has too low avidity to interfere with IL-1
adequately within the joint. However, the
fact that IL-1 is induced by TNF in therheumatoid synovium (Brennan et al.,
1989) and that TNF-mediated experimen-
tal arthritis acts via IL-1 to a large extent
(Zwerina et al., 2007) suggests that there
may be a role for IL-1 in RA.ImmIL-6 is probably the most abundant
cytokine present in the joint. IL-6 is
induced by TNF and IL-1 and is the major
activator of the hepatocytes’ acute phase
response. Its actual receptor, the IL-6Ra
chain, employs an accessory molecule,
gp 130, for signal transduction and cell
activation. Importantly, gp130 can be
activated by both the transmembrane
IL-6Ra and its soluble form via trans-
signaling (Rose-John et al., 2006). Em-
ployment of a humanized antibody to the
IL-6Ra chain allows targeting of both the
membrane-bound and the soluble
IL-6Ra. This antibody, in combination
with MTX, appears to convey a similar
efficacy as TNF inhibitors, with 50% or
more clinical improvement observed in
44% of the patients and 11% of controls
(Smolen et al., 2008). Moreover, mono-
therapy with tocilizumab had good in-
hibitory effects on progression of joint
destruction (Nishimoto et al., 2007). Inter-
estingly, IL-6 inhibition with tocilizumab is
also highly efficacious in the treatment of
systemic-onset juvenile arthritis (Yokota
et al., 2008). Tocilizumab might become
approved in Europe in the near future.
Strategies to eliminate B cells with rit-
uximab (anti-CD20) have also been
shown to be effective in RA, with about
34% of patients (and 13% controls)
attaining at least 50% improvement
(Emery et al., 2006), and this is now also
a licensed therapy of RA. Dampening of
T cell activation with a costimulation
inhibitor, abatacept, a construct of cyto-
toxic T lymphocyte antigen-4 (CTLA-4)
fused to an Fc portion of an immunologo-
bulin G molecules (CTLA-4-Ig), is also an
effective and approved treatment option
for RA. This compound binds to the costi-
mulatory molecules CD80 and CD86 on
APC and thus prevents their interaction
with their receptor on T cells, CD28, pre-
sumably interfering with T cell activation.
Abatacept entails at least 50% clinical
improvement in 48% of RA patients (con-
trols: 18%) (Kremer et al., 2006).
Challenges of Biological Targeted
Therapies
With the advent of biological therapies,
the outcome of RA has changed dramati-
cally. Nevertheless, we are far from an op-
timal situation for a number of reasons.
First, the hierarchy in the course of
pathogenetic events is still unresolved.
For example, as mentioned before,unity 28, April 2008 ª2008 Elsevier Inc. 441
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geting of T cell costimulation, TNF, IL-1, or
IL-6. But these cytokines activate those
cells, and those cells either directly or
via other products (autoantibodies, lym-
phokines) induce the production of these
cytokines—therefore, what goes first,
the hen or the egg? And if we knew it,
would it matter to our therapeutic
approach? Would we give one specific
treatment before the other one?
Second, with regard to noncytokine-di-
rected, targeted therapies, it is not clear at
present howB cell depletion affects RA. Is
it by eliminating precursors of autoanti-
body-producing cells? Is it by eliminating
putative antigen-presenting B cells? Is it
by eliminating cells that can also contrib-
ute to the pool of cytokine producers? Is
it necessary to deplete the B cells, or
would it be sufficient to interfere with
some B cell functions that could be con-
veyed by a nondepleting B cell-directed
therapy? And when it comes to abata-
cept, is its mode of action solely related
to its capacity to inhibit T cell costimula-
tion or to other effects, such as reverse
signaling in ligand-expressing antigen-
presenting cells, thus, again, potentially
inhibiting production of proinflammatory
cytokines?
Third, as briefly mentioned above, Eta-
nercept, in contrast to the monoclonal
antibodies against TNF, is ineffective in
Crohn’s disease—why is this the case,
given that its effect is comparable in RA,
AS, and PsA? One hypothesis suggests
that Etanercept may have less apoptotic
potential on intestinal T cells as compared
to monoclonal antibodies. On the other
hand, an anti-TNF Fab’ fragment also
does not induce apoptosis but still
improves Crohn’s disease (Nesbitt et al.,
2007). Alternatively, Etanercept may
affect bacterial lipopolysaccharide-in-
duced IL-1production toamuch lesser ex-
tent than anti-TNF (Nesbitt et al., 2007),
although it is not clear whether this is the
reason for the differential therapeutic ef-
fects in Crohn’s disase. A further notion in
this respect relates to the observation
that TNF-R2 is upregulated in Crohn’s
disease and that its overexpression in
experimental systems promotes bowel
inflammation (Holtmann et al., 2002). One
might speculate that the intestinal TNF-
R2 molecules, once overexpressed, at-
tract more local TNF than can be bound
by the circulating TNF-R2 construct.442 Immunity 28, April 2008 ª2008 ElsevierAnother interesting observation relates
to the often good efficacy of a second
TNF inhibitor once the initial TNF-inhibitor
has failed to convey therapeutic benefit
(Hyrich et al., 2007). Of course, this may
have pharmacogenomic reasons, but it
is a riddle nevertheless and shows the
complexity of therapeutic decision mak-
ing even with similar targeted therapies.
Why Do We Fail to See Additive
Effects of Targeted Therapies?
All biological therapies currently applied
have better efficacy if combined with syn-
thetic drugs used in RA, such as metho-
trexate.What are themechanisms leading
to this increase in benefit compared to
monotherapy with biological agents? On
the other hand, one would postulate that
targeting several specific molecules
involved in pathways leading to the dis-
ease with two (or more) biologicals would
have added benefit. Alas, neither combi-
nations of inhibitors of different cytokines
nor of different pathways (Weinblatt et al.,
2006) have demonstrated clinical advan-
tages so far. The adverse events, how-
ever, especially the rates of infections,
were increased, suggesting that the com-
bination led to the inhibition of both tar-
gets, albeit without a beneficial effect on
the inflammatory response in RA.
On the other hand, denosumab, an
antibody directed to receptor activator
of nuclear factor kappa B ligand (RANKL),
a pivotal molecule for the differentiation
and activation of osteoclasts, may specif-
ically inhibit osteoclast activation and
bone destruction and thus could be
a sound candidate for combination ther-
apy with agents that have good effects
on symptoms but lesser effects on bone
damage. However, this antibody does
not appear to halt progression of cartilage
damage (van der Heijde et al., 2007).
Thus, the question arises whether the
mere inhibition of bone but not cartilage
damage will be sufficient to interfere with
long-term disability in RA.
What Are the Best Ways of
Targeting the Effects of a Cytokine?
It was previously discussed that Anakinra
(L-1Ra) appears to have only little efficacy
in RA and that this could be due to a com-
bination of a compound with relatively low
avidity to the receptor and a disease
involving a distant region, the joint, and
that the effects of antibodies targetingInc.IL-1 remain to be seen. A further open
question is also whether it is better to tar-
get the IL-6R than to target just IL-6.
Also with respect to TNF inhibition there
are a variety of open issues. TNF signals
via at least two receptors, the p55 and
the p75 receptors, which have different
though partly overlapping effects (Holt-
mann and Neurath, 2004). As mentioned
above, TNF-R2 (but not TNF-R1) appears
to be overexpressed in Crohn’s disease.
In experimental arthritis of mice overex-
pressing soluble TNF, TNF-R1 appears
to be driving inflammation and especially
osteoclast-mediated destruction. Inter-
estingly, the absence of TNF-R2 led to
an increase not only of synovial inflamma-
tion but also joint destruction, indicating
a dual mechanism of TNF (Blueml et al.,
2007). Thus, rather than targeting TNF, it
may be worthwhile to target different
TNF receptors in different diseases
(Holtmann and Neurath, 2004), leaving
the other TNF-signaling pathway intact
and thereby possibly increasing safety.
When Will We Be Able to
Individualize Therapy?
It is currently not possible to predict which
patients will respond to what extent to
which type of treatment. Aside from syn-
thetic agents, whose mode of action has
not been ultimately revealed,we have ther-
apies available that specifically target cos-
timulation, B cells, TNF, IL-1, and, in the fu-
ture, IL-6. These therapies are effective in
many patients—but still we have no clue
in whom these treatments will work well
andwhether thepatientswith verygood re-
sponses are distinct populations for each
of these or constitute overlapping groups.
Currently availablebiomarkers,with theex-
ception of acute-phase reactants, have lit-
tle predictive capacity with regard to clini-
cal outcomes or joint damage.
How Good Are We Really?
Currently, we can achieve stringent remis-
sions, i.e., no evidence of active disease,
with consequential therapy in about 20%
of the patients in clinical practice. How-
ever, cure is not yet in sight. Although
cure will ultimately require knowing the
cause or causes of these disorders, it is
conceivable that interference with the
vicious cycle of the inflammatory occur-
rences very early in the course of the dis-
ease processmay reverse the events usu-
ally destined to become chronic in
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opportunity is addressed by currently on-
going clinical trials, and it remains to be
seen if this hypothesis can come true.
And What About the Risks of
Targeted Therapeutics?
In these types of therapies, there is rarely
a benefit without potential harm. All com-
pounds above block cellular and/or mo-
lecular functions that presumably have
an important role in the healthy host. Fore-
most, TNF, IL-1, and IL-6 play important
roles in host defense both in the innate
and adaptive immune systems. There-
fore, one should expect an increase in
the rates of infections, which is the case
(Smolen et al., 2007; Cohen et al., 2002;
Emery et al., 2006; Kremer et al., 2006;
Smolen et al., 2008). For example, TNF
plays a pivotal role in granuloma forma-
tion and, therefore, in the defense against
intracellular pathogens. Indeed, reactiva-
tion of tuberculosis has been observed
with TNF inhibitors. In contrast, IL-6 may
have an inhibiting role on granuloma for-
mation (Nagabhushanam et al., 2003);
therefore, targeting IL-6 therapeutically
might not induce reactivation of, or pro-
mote infections with, some intracellular
pathogens.
Other aspects relate to increases in
lipid levels in the course of IL-6 inhibition.
It remains to be seen whether cardiovas-
cular risk increases. Presently, rather the
reverse has been observed in patients in
whom inflammatory disease was suc-
cessfully treated and lipids increased as
a consequence of the anti-inflammatory
treatment effects. IL-6 is also a growth
factor for hepatocytes, and tocilizumab
leads to increases in hepatic enzymes,
which are usually of transient nature and
not associated with hepatitis (Smolen
et al., 2008). However, long-term follow
up will have to show whether this might
be associated with liver damage. Given
that TNF inhibition also leads to normali-
zation of IL-6 (Charles et al., 1999) but
not to liver enzyme elevations, it will also
be of interest to learn whether a monoclo-
nal anti-IL-6, rather than an antibody to
the IL-6R, will induce a similar adverse
event profile.
Some of these biological agents are
chimeric or humanized monoclonal anti-
bodies. Therefore, sensitization might oc-
cur, which can lead to both allergic reac-
tions and reduction in efficacy.Future Directions
Finally, many additional molecules are po-
tential targets for future effective thera-
pies. These comprise other cytokines
than those currently aimed at and signal-
transduction molecules. For example,
inhibition of Jak3, in early studies, has
shown an interesting efficacy profile
(Breedveld et al., 2007).
How can one learn more about early
effects of such agents? One way might
be to employ in vivo microscopy, which
has successfully been used already else-
where (Castellino et al., 2006), in experi-
mental models of arthritis in the course
of application of these treatments. This
could allow some of the tantalizing ques-
tions to be answered: When different mol-
ecules or cells are targeted, will the com-
position of the synovial inflammation
change dependent on the compound
employed? Or, do all T cells present in
arthritic joints of animals with antigen-
mediated arthritis have antigen specific
properties? Or, what are the earliest
immunologic events within the joint in dif-
ferent forms of experimental arthritis, and
how do they react to different treatment
modalities? Although the answers may
not necessarily translate fully to the hu-
man situation, they may at least give
a clue on which cells may be initially af-
fected and what these effects mean in
the context of the cellular composition of
the synovial membrane and the cytokine
profile expressed. Another important
aspect relates to prospects to predict se-
verity of disease and response to therapy.
It is here where there is hope for deeper
insights to be gained by genomic and pro-
teomic analyses—but this will also have to
await better-designed comparative clini-
cal trials that allow the respective ques-
tions to be asked.
In summary, targeting of proinflamma-
tory cytokines such as TNFor IL-6 is highly
efficacious in rheumatoid arthritis and, at
least for anti-TNF agents, also other
chronic inflammatory rheumatic and non-
rheumatic inflammatory disorders. They
substantially improve signs and symp-
toms and retard or prevent organ damage
and disability, the most devastating con-
sequence of these chronic conditions.
Although the progress made over the
past dozen or so years has dramatically
improved the fate of the patients, we still
lack sufficient predictive insights to deter-
mine the optimal therapeutic strategy forImmthe individual patient. Moreover, despite
all these advances, the overall rate of
good responses is limited, with only about
10%–40% of patients achieving improve-
ment of 70%ormorewith any one of these
agents based on clinical scoring. Thus,
although with increasing therapeutic
options an increasing number of patients
will achieve a good clinical result and,
ideally, remission, new compounds with
even better efficacy and better safety will
still be needed. In parallel, the search for
causes, the search for predictors, and
the search for explanations of the effects
of many of these therapies will have to
go on.
ACKNOWLEDGMENTS
J.S.S. received honoraria and/or grant support
from Abbott, Amgen, BMS, Centocor/Schering-
Plough, Novartis, Roche, Sanofi-Aventis, UCB,
and Wyeth.
REFERENCES
Blueml, S., Binder, N., Polzer, K., Tuerk, B.,
Scheinecker, C., Smolen, J., and Redlich, K.
(2007). Ann. Rheum. Dis. 66 (Suppl II), 120.
Breedveld, F.C., Bloom,B.J., Coombs, J., Fletcher,
M.P., Gruben, D., Kremer, J.M., Krishnaswami, S.,
Burgos-Vargas, R., Zerbini, C., Wilkinson, B., and
Zwillich, S.H. (2007). Ann. Rheum. Dis. 66 (Suppl
II), 441.
Brennan, F.M., Chantry, D., Jackson, A., Maini, R.,
and Feldmann, M. (1989). Lancet 2, 244–247.
Castellino, F., Huang, A.Y., Altan-Bonnet, G.,
Stoll, S., Scheinecker, C., and Germain, R.N.
(2006). Nature 440, 890–895.
Charles, P., Elliott, M.J., Davis, D., Potter, A.,
Kalden, J.R., Antoni, C., Breedveld, F.C., Smo-
len, J.S., Eberl, G., deWoody, K., et al. (1999).
J. Immunol. 163, 1521–1528.
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt,
M.E., Moreland, L.W., Kremer, J., Bear, M.B., Rich,
W.J., and McCabe, D. (2002). Arthritis Rheum. 46,
614–624.
Elliott, M.J., Maini, R.N., Feldmann, M., Kalden,
J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld,
F.C., Macfarlane, J.D., and Bijl, H. (1994). Lancet
344, 1105–1110.
Emery, P., Fleischmann, R., Filipowicz-Sosnow-
ska, A., Schechtman, J., Szczepanski, L., Kava-
naugh, A., Racewicz, A.J., van Vollenhoven, R.F.,
Li, N.F., Agarwal, S., et al. (2006). Arthritis Rheum.
54, 1390–1400.
Goldbach-Mansky, R., Dailey, N.J., Canna, S.W.,
Gelabert, A., Jones, J., Rubin, B.I., Kim, H.J.,
Brewer, C., Zalewski, C., Wiggs, E., et al. (2006).
N. Engl. J. Med. 355, 581–592.
Holtmann, M.H., and Neurath, M.F. (2004). Curr.
Mol. Med. 4, 439–444.
Holtmann, M.H., Douni, E., Schutz, M., Zeller, G.,
Mudter, J., Lehr, H.A., Gerspach, J., Scheurich,unity 28, April 2008 ª2008 Elsevier Inc. 443
Immunity
CommentaryP., Galle, P.R., Kollias, G., and Neurath, M.F.
(2002). Eur. J. Immunol. 32, 3142–3151.
Hyrich, K.L., Lunt, M., Watson, K.D., Symmons,
D.P., and Silman, A.J. (2007). Arthritis Rheum. 56,
13–20.
Kremer, J.M., Genant, H.K., Moreland, L.W., Rus-
sell, A.S., Emery, P., Abud-Mendoza, C., Szechin-
ski, J., Li, T., Ge, Z., Becker, J.C., andWesthovens,
R. (2006). Ann. Intern. Med. 144, 865–876.
Nagabhushanam, V., Solache, A., Ting, L.M.,
Escaron, C.J., Zhang, J.Y., and Ernst, J.D.
(2003). J. Immunol. 171, 4750–4757.
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P.,
Stephens, S., Foulkes, R., Brown, D., Robinson,
M., and Bourne, T. (2007). Inflamm. Bowel Dis.
13, 1323–1332.444 Immunity 28, April 2008 ª2008 ElsevierNishimoto, N., Hashimoto, J., Miyasaka, N., Yama-
moto, K., Kawai, S., Takeuchi, T., Murata, N., van
der Heijde, D., and Kishimoto, T. (2007). Ann.
Rheum. Dis. 66, 1162–1167.
Rose-John, S., Scheller, J., Elson, G., and Jones,
S.A. (2006). J. Leukoc. Biol. 80, 227–236.
Sandborn, W.J., and Targan, S.R. (2002). Gastro-
enterology 122, 1592–1608.
Smolen, J.S., Han, C., Bala, M., Maini, R., Kalden,
J., van der Heijde, D., Breedveld, F.C., Furst, D.E.,
and Lipsky, P.E. (2005). Arthritis Rheum. 52, 1020–
1030.
Smolen, J.S., Aletaha, D., Koeller, M., Weisman,
M., and Emery, P. (2007). Lancet 370, 1861–1874.
Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ra-
mos-Remus, C., Rovensky, J., Alecock, E., Wood-Inc.woth, T., and Alten, R. (2008). Lancet 371, 987–
997.
van der Heijde, D., Cohen, S.B., Sharp, J.T., Ory,
P., Zhou, L., Tsuji, W., and Newmark, R. (2007).
Ann. Rheum. Dis. 66 (Suppl II), 89.
Weinblatt, M., Combe, B., Covucci, A., Aranda, R.,
Becker, J.C., and Keystone, E. (2006). Arthritis
Rheum. 54, 2807–2816.
Yokota, S., Imagawa, T., Mori, M., Miyamae, T.,
Aihara, Y., Takei, S., Iawata, N., Umebayashi,
H., Murata, T., Miyoshi, M., et al. (2008). Lancet
371, 998–1006.
Zwerina, J., Redlich, K., Polzer, K., Joosten, L.,
Kronke, G., Distler, J., Hess, A., Pundt, N., Pap,
T., Hoffmann, O., et al. (2007). Proc. Natl. Acad.
Sci. USA 104, 11742–11747.
